Likelihood of Approval and Phase Transition Success Rate Model – Ixazomib Citrate in Secondary Progressive Multiple Sclerosis (SPMS)
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Ixazomib Citrate in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Ixazomib Citrate in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:
Ixazomib citrate (MLN9708 / Ninlaro) acts as an anti neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. It is under development of cold agglutinin disease (cAIHA) and relapsed or refractory light chain amyloidosis, immune thrombocytopenia (ITP), interstitial lung disease, relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma, kidney cancer(second-line therapy), advanced solid tumors including urothelial cell cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma and glioblastoma multiforme, acute and chronic myelogenous leukemia, relapsing remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis, acute and chronic lymphocytic leukemia, low-grade, intermediate Hodgkin and non-Hodgkin lymphoma, mantle cell lymphoma, plasmablastic lymphoma, angioimmunoblastic T-cell lymphoma (AITL). It was also under development for newly diagnosed multiple myeloma, hematological malignancies including relapsed/refractory acute myeloid leukemia (AML), Waldenstrom macroglobulinemia, head and neck cancer squamous cell carcinoma, soft tissue sarcoma and prostate cancer, lupus nephritis, systemic lupus erythematosus, refractory autoimmune cytopenia including warm autoimmune hemolytic anemia (wAIHA), relapsed/refractory primary amyloidosis, metastatic renal cell carcinoma, metastatic triple negative breast cancer, high risk myelodysplastic syndrome, relapsed /refractory cutaneous T-cell lymphoma, sezary syndrome, mycosis fungoides, anaplastic large cell lymphoma (ALCL), diffuse large B-cell lymphoma and peripheral T-cell lymphomas (PTCL), intravenous pediatric patients with relapsed/refractory acute lymphoblastic leukemia, relapsed/refractory lymphoblastic lymphoma and graft versus host disease. It ws also under development for the treatment of Burkitt lymphoma.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Ixazomib Citrate LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports